EIS - ETF AI Analysis
Top Page
iShares MSCI Israel ETF (EIS)
EIS, the iShares MSCI Israel ETF, has a solid but not top-tier rating, largely supported by strong Israeli financial institutions like Bank Leumi, Poalim, Phoenix, and Mizrahi Tefahot Bank, which show healthy financial performance, reasonable or attractive valuations, and generally positive technical trends. These strengths are partly offset by holdings such as Teva and Enlight Renewable Energy, where debt, cash flow, and valuation concerns introduce more uncertainty. The main risk factor is the fund’s concentration in a single country, Israel, which can increase exposure to local economic and geopolitical events.
EIS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 867.55M
- Region
- Middle East & Africa
- Expense Ratio
- 0.59%
- Beta
- 0.77
- Issuer
- iShares
- Inception Date
- Mar 26, 2008
- Dividend Yield
- 1.55%
- Asset Class
- Equity
- Index Tracked
- MSCI Israel Capped Index
EIS Summary
EIS is the iShares MSCI Israel ETF, which follows the MSCI Israel Capped Index to give you broad exposure to the Israeli stock market. It holds a mix of companies across many sectors, including well-known names like Teva Pharmaceutical and Leumi bank. Investors might consider EIS to diversify beyond the U.S., tap into Israel’s technology and healthcare growth, and gain access to a different regional economy in a single investment. However, because it focuses heavily on one country, its price can move up or down sharply with changes in Israel’s market and regional politics.
How much will it cost me?
The iShares MSCI Israel ETF (EIS) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is passively managed but focuses on a niche market, which can involve higher costs to track the index effectively.
What would affect this ETF?
The iShares MSCI Israel ETF (EIS) could benefit from Israel's strong presence in technology and healthcare, sectors known for innovation and growth potential. However, challenges such as geopolitical tensions in the Middle East or changes in global interest rates affecting financial institutions could negatively impact the ETF's performance. Investors should also consider how broader economic conditions and regulatory changes in Israel might influence its top holdings, including major banks and tech companies.
EIS Top 10 Holdings
EIS is essentially a pure play on Israel, and its story right now is being written by a handful of heavyweight names. Teva Pharmaceutical is rising and acting as a key engine for the fund, while big banks like Leumi and Poalim provide a steady, supportive backbone as financials quietly pull their weight. On the flip side, chipmaker Tower and tech name Nova have been lagging lately, taking some shine off the fund’s tech tilt. Defense player Elbit and renewable-energy firm Enlight add a more volatile, mixed-performance edge to this Israel-focused mix.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TEVA | Teva Pharmaceutical | 11.96% | $104.06M | $48.27B | 107.40% | 63Neutral |
 IL:LUMI | Leumi | 8.74% | $75.99M | ILS 109.67B | 25.83% | 80Outperform |
 IL:POLI | Poalim | 8.01% | $69.66M | ILS 100.49B | 28.68% | 79Outperform |
 IL:TSEM | Tower | 5.66% | $49.21M | ILS 68.71B | 159.98% | ―― |
 IL:ESLT | Elbit Systems | 5.15% | $44.80M | ILS 107.89B | 47.42% | 73Outperform |
 IL:DSCT | Discount | 3.36% | $29.25M | ILS 42.35B | 16.29% | 75Outperform |
 IL:PHOE | Phoenix | 3.24% | $28.15M | ILS 45.45B | 58.75% | 79Outperform |
 IL:MZTF | Mizrahi Tefahot | 2.91% | $25.30M | ILS 61.00B | 19.15% | 80Outperform |
 IL:NVMI | Nova | 2.55% | $22.14M | ILS 31.62B | -7.51% | ―― |
 ENLT | Enlight Renewable Energy | ― | ― | ― | ― | 77Outperform |
EIS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EIS, the sentiment is Neutral. The current price of 119.65 is below the 20-day moving average (MA) of 121.11, below the 50-day MA of 122.50, and below the 200-day MA of 122.58, indicating a bearish trend. The MACD of -1.22 indicates Positive momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 55.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EIS.
EIS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| EIS | $119.65 | $129.00(7.81% Upside) | $867.55M | 0.59% | 60Neutral |
 DMXF | $83.26 | $100.82(21.10% Upside) | $1.02B | 0.12% | 65Neutral |
 JHMD | $44.31 | $51.85(17.02% Upside) | $986.53M | 0.39% | 65Neutral |
 HLAL | $73.33 | $91.16(24.31% Upside) | $982.17M | 0.50% | 76Outperform |
 AUSF | $50.63 | $57.33(13.22% Upside) | $882.87M | 0.27% | 71Outperform |
 ISRA | $64.71 | ― | $155.32M | 0.59% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EIS | iShares MSCI Israel ETF | 119.65 | 22.50 | 23.16% | |
| DMXF | iShares ESG Advanced MSCI EAFE ETF | 83.26 | 9.31 | 12.59% | |
| JHMD | John Hancock Multifactor Developed International ETF | 44.31 | 5.23 | 13.39% | |
| HLAL | Wahed FTSE USA Shariah ETF | 73.33 | 13.00 | 21.55% | |
| AUSF | Global X Adaptive U.S. Factor ETF | 50.63 | 5.96 | 13.33% | |
| ISRA | VanEck Israel ETF | 64.71 | 11.47 | 21.54% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.